Results 161 to 170 of about 69,132 (251)

Successful Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis, Myositis, and Myasthenia Overlap Syndrome With Baricitinib and Abatacept. [PDF]

Clin Case Rep
Alnahas Z, Sarkar S, Roychoudhury O, Algabre E.   +3 more
europepmc   +1 more source

Immunotherapeutic Approaches to Head and Neck Squamous Cell Carcinoma: Current Clinical Practice and Future Directions

Head &Neck, Volume 48, Issue 9, Page 2584-2592, September 2026.
ABSTRACT Background Head and neck squamous cell carcinoma (HNSCC) is frequently diagnosed at advanced stages and has historically been associated with poor outcomes. Immune checkpoint inhibition has transformed the therapeutic landscape, offering durable responses in recurrent, metastatic, and locally advanced disease.
Carol R. Bradford, Sreeram M. P., Karthik N. Rao, Orlando Guntinas‐Lichius, Nabil Saba, Alfio Ferlito   +5 more
wiley   +1 more source

Immune checkpoint inhibitors in medulloblastoma: current updates in preclinical and clinical developments. [PDF]

Front Oncol
Welch RL, Moziak K, Zang X, Martin AM.
europepmc   +1 more source

Nanomaterial‐Mediated Radiotherapy–Immunotherapy Combinations: Breaking Immunosuppression and Revolutionizing Cancer Treatment

MedComm – Biomaterials and Applications, Volume 5, Issue 3, September 2026.
Nanomaterials integrate radiotherapy and immunotherapy by enhancing radiosensitivity, remodeling the immunosuppressive tumor microenvironment, and promoting systemic antitumor immunity. This review summarizes the latest strategies of nanomaterial‐mediated combinations (RT, immunotherapy, IRT) and highlights future directions for overcoming clinical ...
Peijie Li, Xiangqin Wang, Sisi He, Hu Ma
wiley   +1 more source

Immune Checkpoint-Based Therapies in Colorectal Cancer-Current Approaches and Future Perspectives. [PDF]

Int J Mol Sci
Nakielska K, Plewka J, Lenart M.
europepmc   +1 more source

Inflammatory Bowel Disease: Mechanisms and Therapeutic Advances

MedComm, Volume 7, Issue 9, September 2026.
Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn's disease, is a rising, multifactorial chronic disorder driven by dysregulated mucosal immunity in genetically susceptible individuals and influenced by environmental and microbial factors.
Andrea Papait, Anna Cargnoni, Franco Scaldaferri, Loris Lopetuso, Antonietta Rosa Silini, Ornella Parolini   +5 more
wiley   +1 more source

Phenotypic, functional, prognostic and predictive significance of B-cell and antibody responses in human melanoma: a scoping review. [PDF]

Br J Dermatol
Booth L, Chen X, Stoker K, McCraw A, Tahiri M, Wu Y, Geh JLC, MacKenzie Ross AD, Lloyd-Hughes H, Lacy KE, Whittaker S, Jacków-Malinowska J, Van Hemelrijck M, Tull TJ, Tsoka S, Karagiannis SN.   +15 more
europepmc   +1 more source

Oral lichenoid lesions in CTLA‐4 haploinsufficiency: Targeting IFN‐γ‐driven mucosal immunopathology

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Chen Wang, Laurie Brenchley, Teresa Greenwell‐Wild, Vasileios Ionas Theofilou, Timothy G. Myers, Chi A. Ma, Katherine Howe, Stefania Pittaluga, Steven M. Holland, Niki M. Moutsopoulos, David Fraser, Gulbu Uzel   +11 more
wiley   +1 more source

Restricted TCR Diversity and Expansion of CD177+CD8+ and TLR4+CD4+T Cell Subsets in Septic Shock‐Associated Immunosuppression: A Single‐Cell Multi‐Omics Study

MedComm, Volume 7, Issue 9, September 2026.
Our study enrolled 10 septic shock patients with immunosuppression and 10 healthy controls and sorted CD8+ and CD4+ T cells for transcriptome sequencing. Disease‐specific cell types, key transcripts, and TCR features were identified using integrated analysis.
Yawen Xie, Xunyao Wu, Guoyu Zhao, Xianli Lei, Jiahui Zhang, Na Cui, Bin Du   +6 more
wiley   +1 more source

Targeting regulatory T cells in the prostate cancer microenvironment: From mechanisms to therapeutics (Review). [PDF]

Mol Med Rep
Luo H.
europepmc   +1 more source